GLP-1 Receptor Agonists: Originally developed for type 2 diabetes, drugs like liraglutide and semaglutide have demonstrated potent neuroprotective effects in preclinical models of both AD and vascular injury. Here, GLP1R is linked to Alzheimer disease.